# Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular

> **NCT07352007** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Lei ZHAO** · enrollment: 110 (estimated)

## Conditions studied

- HCC

## Interventions

- **PROCEDURE:** SBRT
- **DRUG:** Sintilimab
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT07352007
- **Lead sponsor:** Lei ZHAO
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-28
- **Primary completion:** 2028-01-20
- **Final completion:** 2031-01-20
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07352007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07352007, "Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT07352007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*